Aktienanalyse zu Citius Oncology Inc (CTOR)CTORCitius Oncology Inc

Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. It operates in the Healthcare sector.

Citius Oncology Inc appears to be a good buy right now due to its recent sales growth, with LYMPHIR sales increasing by 120% in Q4 2026, and the stock's current price of $0.59 being significantly below its 52-week high of $1.83, suggesting potential for recovery. However, the company reported a net loss of $26.61 million in Q2 2026, which poses a risk to its financial stability.